Danaher Co. (NYSE:DHR) is Bradley Foster & Sargent Inc. CT’s 6th Largest Position

Bradley Foster & Sargent Inc. CT reduced its holdings in shares of Danaher Co. (NYSE:DHR) by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 605,423 shares of the conglomerate’s stock after selling 569 shares during the quarter. Danaher comprises 2.3% of Bradley Foster & Sargent Inc. CT’s investment portfolio, making the stock its 6th biggest position. Bradley Foster & Sargent Inc. CT owned about 0.08% of Danaher worth $138,975,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Heck Capital Advisors LLC bought a new stake in shares of Danaher during the fourth quarter valued at about $27,000. Decker Retirement Planning Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $31,000. Golden State Wealth Management LLC purchased a new stake in Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher in the 3rd quarter valued at $39,000. Finally, MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher during the 3rd quarter valued at $40,000. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Up 1.5 %

Shares of NYSE DHR opened at $208.10 on Friday. The company has a market cap of $150.31 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.61 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm’s fifty day moving average is $227.21 and its 200 day moving average is $247.52. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business earned $2.09 earnings per share. On average, equities research analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.32 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Wells Fargo & Company dropped their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Raymond James restated a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price for the company. Finally, Citigroup decreased their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.